ProcureCon Pharma is coming to Philadelphia for the 2016 conference starting on October 26! The three day event attracts procurement and strategic sourcing professionals from industry leading pharmaceutical companies including AstraZeneca, Otsuka, Bristol-Myers Squibb, GlaxoSmithKline, and more for engaging sessions addressing the unique challenges facing pharma procurement groups. Attendees anticipate a full agenda of panels, workshops, and roundtables designed to provide procurement professionals with strategies for managing costs and driving value in procurement and sourcing processes.

The first day of ProcureCon Pharma will exclusively welcome procurement executives to discuss using procurement to drive value in today’s fluctuating pharmaceutical industry. The following day focuses on strengthening internal and external partnerships to further today’s procurement organization and the final day of the event will examine the future of procurement and what to expect when preparing for the needs of your business down the road. Between presentations from industry leaders including Johnson and Johnson, Takeda Pharmaceuticals, and Boehringer Ingelheim USA, and more, daily panel discussions and roundtables generate progressive conversation that continue during networking opportunities in the evening. 

Among the roster of anticipated speakers is Source One’s Director David Pastore. Pastore’s session, titled From Value, will explore the ways Procurement groups can demonstrate their value beyond cost reduction. Procurement has evolved passed a tactical purchasing role, and is quickly being leveraged as a strategic function for achieving overarching company-wide goals. As a result, companies need to reevaluate their approach to measuring Procurement's performance and communicating their success. Pastore will share how capitalizing on the growing discipline of data science for procurement can teach your team to exhibit progress on management-driven procurement and sourcing goals. 
Share To:

Strategic Sourceror

Post A Comment:

0 comments so far,add yours